We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesTetraLogic Pharmaceuticals Corp

TetraLogic Pharmaceuticals Corp

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.0001 USD 0.00(0%)
Last update at 2026-11-11T21:00:00Z
VOLUME
400
Market Cap
0.00M

Momentum Score

…

TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. It has two clinical-stage product candidates in development, such as birinapant and SHAPE. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to apoptosis or cell-death in damaged cells. SHAPE is its proprietary histone deacetylase inhibitor for topical use for the treatment of early-stage cutaneous T-cell lymphoma. TetraLogic Pharmaceuticals Corporation has research collaboration with Walter and Eliza Hall Institute of Medical Research to examine SMAC-mimetics, including birinapant in the treatment of infectious disease. The company was formerly known as Gentara Corporation and changed its name to TetraLogic Pharmaceuticals Corporation in January 2006. TetraLogic Pharmaceuticals Corporation was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
-
Low
0.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

TetraLogic Pharmaceuticals Corp is a small, development-stage pharmaceutical company listed on the OTC Pink market; public disclosures are limited, which constrains detailed assessment. Its long-term growth may depend on successful clinical or preclinical development, regulatory approvals, licensing or partnerships, and the ability to raise capital, outcomes that could support value creation if achieved.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-4.76
ROE
-
Net Debt
12.98M
ROCE
-74.54%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2015-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2015-12-31
Income before tax - - - - -49.72M
Net income - - - - -56.11M
Selling general administrative - - - - 11.10M
Gross profit - - - - 0.00M
Ebit - - - - -44.99M
Ebitda - - - - -38.21M
Depreciation and amortization 0.23M 0.24M 0.21M 0.17M 6.78M
Non operating income net other - - - - 1.65M
Operating income - - - - -44.99M
Other operating expenses - - - - 38.50M
Interest expense - - - - 6.38M
Non recurring - - - - 16.90M
Income tax expense - - - - 6.38M
Total revenue - - - - 0.00M
Total operating expenses - - - - 38.50M
Cost of revenue - - - - 38.31M
Total other income expense net - - - - -4.73M
Net income from continuing ops - - - - -49.72M
Net income applicable to common shares - - - - -49.72M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2015-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2015-12-31
Total assets - - - - 64.02M
Intangible assets - - - - 41.58M
Other current assets - - - - 1.56M
Total liab - - - - 69.96M
Total stockholder equity - - - - -5.94M
Deferred long term liab - - - - 16.88M
Other current liab - - - - 3.25M
Common stock - - - - 0.00M
Retained earnings - - - - -175.56M
Other liab - - - - 37.97M
Other assets - - - - 0.06M
Cash - - - - 15.30M
Total current liabilities - - - - 3.66M
Net debt - - - - 12.98M
Short term debt - - - - 28.33M
Short long term debt - - - - 28.33M
Short long term debt total - - - - 28.28M
Other stockholder equity - - - - 169.68M
Property plant equipment - - - - 0.42M
Total current assets - - - - 21.97M
Net tangible assets - - - - -47.52M
Short term investments - - - - 5.11M
Long term debt - - - - 28.33M
Accounts payable - - - - 0.41M
Accumulated other comprehensive income - - - - -0.07M
Non currrent assets other - - - - 0.06M
Non current assets total - - - - 42.05M
Breakdown 2015-12-31 2014-12-31 2013-12-31 2012-12-31 2011-12-31
Type yearly yearly yearly yearly yearly
Date 2015-12-31 2014-12-31 2013-12-31 2012-12-31 2011-12-31
Investments 35.52M -40.63M -40.63M 5.53M -
Change to liabilities -1.21M 0.57M 0.87M -0.55M -
Total cashflows from investing activities 35.45M -53.98M -0.07M 5.50M -
Net borrowings -0.83M 44.15M 14.24M 4.93M -
Total cash from financing activities 1.79M 44.35M 63.46M 4.94M 7.12M
Change to operating activities 2.29M -3.38M 0.54M 0.32M -
Net income -49.72M -35.96M -19.95M -16.20M -18.92M
Change in cash 2.23M -42.06M 50.62M -5.49M -15.75M
Begin period cash flow 13.07M 55.14M 4.51M 10.01M 25.76M
End period cash flow 15.30M 13.07M 55.14M 4.51M 10.01M
Total cash from operating activities -34.89M -32.37M -12.77M -15.93M -17.33M
Depreciation 0.19M 0.13M 0.10M 0.15M 0.21M
Other cashflows from investing activities - 0.02M 0.02M 0.02M -
Sale purchase of stock 0.03M 0.20M 49.22M 0.00M -
Other cashflows from financing activities 2.62M -53.98M -0.07M 4.97M 7.26M
Change to netincome 13.57M 6.28M 5.67M 0.31M -
Capital expenditures 0.08M 0.51M 0.07M 0.03M 0.01M
Cash flows other operating 2.29M -3.38M - - -
Exchange rate changes -0.12M -0.07M - - -
Cash and cash equivalents changes 2.23M -42.06M - - -
Change in working capital 1.08M -2.81M 1.41M -0.23M 1.05M
Stock based compensation 5.68M 3.38M 3.71M 0.35M 0.27M
Other non cash items -6.70M 3.97M -17.99M 0.04M 0.05M
Free cash flow -34.97M -32.88M -12.84M -15.96M -17.35M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
TLOG
TetraLogic Pharmaceuticals Corp		 -
-%		 0.00 - - - 0.40 -0.01
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

TetraLogic Pharmaceuticals Corp

TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. It has two clinical-stage product candidates in development, such as birinapant and SHAPE. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to apoptosis or cell-death in damaged cells. SHAPE is its proprietary histone deacetylase inhibitor for topical use for the treatment of early-stage cutaneous T-cell lymphoma. TetraLogic Pharmaceuticals Corporation has research collaboration with Walter and Eliza Hall Institute of Medical Research to examine SMAC-mimetics, including birinapant in the treatment of infectious disease. The company was formerly known as Gentara Corporation and changed its name to TetraLogic Pharmaceuticals Corporation in January 2006. TetraLogic Pharmaceuticals Corporation was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

343 Phoenixville Pike, Malvern, PA, United States, 19355

610 889 9900

https://www.tetralogicpharma.com

29

Name Title Year Born
Dr. Yigong Shi Ph.D. Co-Founder 1968
Sarah E. Frew Director of Bus. & Commercial Devel. NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…